Cargando…

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia

Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Hun-Ju, Chuang, Meng-Ni, Chu, Chiao-Lun, Wu, Pei-Lin, Ho, Shu-Chen, Kuo, Ho-Chang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037584/ https://www.ncbi.nlm.nih.gov/pubmed/33808075 http://dx.doi.org/10.3390/jcm10071381

Ejemplares similares

Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Chen, Chih-Jen, et al.
Publicado: (2012)

Kawasaki Disease Increases the Incidence of Myopia
por: Kung, Yung-Jen, et al.
Publicado: (2017)

Comparison of the Laboratory Data Between Kawasaki Disease and Enterovirus After Intravenous Immunoglobulin Treatment
por: Lin, Li-Yan, et al.
Publicado: (2012)

FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2015)

C-Reactive Protein to Albumin Ratio for Predicting Coronary Artery Lesions and Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Tsai, Chih-Min, et al.
Publicado: (2020)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial
por: Kuo, Ho-Chang, et al.
Publicado: (2018)

Prediction of Resistance to Standard Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Lee, Sang Min, et al.
Publicado: (2014)

Plasma Clusterin Concentrations May Predict Resistance to Intravenous Immunoglobulin in Patients with Kawasaki Disease
por: Ou-Yang, Mei-Chen, et al.
Publicado: (2013)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
por: Li, Wei, et al.
Publicado: (2022)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study
por: Kuo, Ni-Chun, et al.
Publicado: (2023)

Prediction for Intravenous Immunoglobulin Resistance by Using Weighted Genetic Risk Score Identified From Genome-Wide Association Study in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2017)

Evaluation of Formosa score and diagnostic sensitivity and specificity of four Asian risk scores for predicting intravenous immunoglobulin resistance in Kawasaki disease: a bivariate meta-analysis
por: Chiang, Wan-Ni, et al.
Publicado: (2023)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone
por: Goto, Masahiro, et al.
Publicado: (2015)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease
por: He, Lan, et al.
Publicado: (2021)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease
por: Van Anh, Khanh-Van Y., et al.
Publicado: (2020)

Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease
por: Lu, Yaheng, et al.
Publicado: (2021)

Treatment of Kawasaki Disease: A Network Meta-Analysis of Four Dosage Regimens of Aspirin Combined With Recommended Intravenous Immunoglobulin
por: Huang, Ying-Hua, et al.
Publicado: (2021)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Impact of Early Treatment With High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children
por: Karimi Yazdi, Alireza, et al.
Publicado: (2021)

Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
por: Hur, Gyu, et al.
Publicado: (2018)

Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study
por: Lin, Ming-Chih, et al.
Publicado: (2013)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Risk Factors and Predictive Models for Intravenous Immunoglobulin Resistance in Children with Recurrent Kawasaki Disease
por: Chen, Xi, et al.
Publicado: (2022)

The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease
por: Chang, Ling-Sai, et al.
Publicado: (2016)

Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease
por: Cha, Sungho, et al.
Publicado: (2008)

Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease
por: Lee, Taek Jin, et al.
Publicado: (2008)

Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease
por: Xie, Tian, et al.
Publicado: (2017)

Comparable bidirectional neutrophil immune dysregulation between Kawasaki disease and severe COVID-19
por: Chen, Kuang-Den, et al.
Publicado: (2022)

Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Kim, Hyun Kwon, et al.
Publicado: (2011)

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease
por: Kemmotsu, Yasushi, et al.
Publicado: (2011)

Peripheric arterial aneurisyms and monocytosis in intravenous immunoglobulin treatment resistant Kawasaki disease
por: Baskin, E, et al.
Publicado: (2008)

Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease
por: Lee, Hye Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_07a56svqjb2sv38fhjru2n66sh